Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical history compatible with chronic hepatitis B infection~Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* Patient is pregnant or breastfeeding~* Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV~* Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog~Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).